|
|
Article: Telormedix Appoints Johanna Holldack as CEO.
- Article from:
- Cancer Vaccine Week
- Article date:
- November 9, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Telormedix, a clinical stage biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases, announced that it has appointed Dr. Johanna Holldack as its new Chief Executive Officer (see also Telormedix).
Dr. Holldack was previously Chief Executive Officer of Borean Pharma, but has also had extensive management experience in a number of other life sciences companies. Her previous posts included Chief Operation's Officer at MediGene AG in Munich, Germany, Vice President of Global Vaccines and Therapeutics at Chiron Corp. in Emeryville, USA and Head of Clinical Research and Development at German Behringwerke AG.
...